Terms: = Liver cancer AND FLT4, FLT41, 2324, ENSG00000037280, P35916, VEGFR3, PCL AND Clinical Outcome
3 results:
1. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
Harmon CS; DePrimo SE; Raymond E; Cheng AL; Boucher E; Douillard JY; Lim HY; Kim JS; Lechuga MJ; Lanzalone S; Lin X; Faivre S
J Transl Med; 2011 Jul; 9():120. PubMed ID: 21787417
[TBL] [Abstract] [Full Text] [Related]
2. Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.
Zhu AX; Duda DG; Ancukiewicz M; di Tomaso E; Clark JW; Miksad R; Fuchs CS; Ryan DP; Jain RK
Clin Cancer Res; 2011 Feb; 17(4):918-27. PubMed ID: 20843836
[TBL] [Abstract] [Full Text] [Related]
3. Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer.
Hirashima Y; Yamada Y; Matsubara J; Takahari D; Okita N; Takashima A; Kato K; Hamaguchi T; Shirao K; Shimada Y; Taniguchi H; Shimoda T
Cancer Sci; 2009 Feb; 100(2):310-5. PubMed ID: 19068081
[TBL] [Abstract] [Full Text] [Related]
